INKT MiNK Therapeutics
- 0.683
- +0.013+1.89%
- 0.683
- 0.0000.00%
MiNK Therapeutics News
MiNK Therapeutics Price Target Maintained With a $9.00/Share by HC Wainwright & Co.
Analysts Are Bullish on These Healthcare Stocks: Black Diamond Therapeutics (BDTX), MiNK Therapeutics (INKT)
MiNK Therapeutics, Autonomous Therapeutics Enter Research Collaboration
Express News | Mink Therapeutics and Autonomous Therapeutics Announce Collaboration to Develop Novel Therapies Targeting Metastatic Tumors
MiNK Therapeutics and Autonomous Therapeutics Announce Collaboration to Develop Novel Therapies Targeting Metastatic Tumors
12 Health Care Stocks Moving In Friday's After-Market Session
MiNK Therapeutics to Present Data From INKT Cell Programs at SITC 2024
MiNK Therapeutics to Participate in H.C. Wainwright Global Investment Conference
Earnings Call Summary | MiNK Therapeutics(INKT.US) Q2 2024 Earnings Conference
Express News | Mink Therapeutics Files for Shelf of up to 4.6 Mln Shares by Selling Stockholder - SEC Filing
MiNK Therapeutics | 10-Q: Q2 2024 Earnings Report
HC Wainwright & Co. Reiterates Buy on MiNK Therapeutics, Maintains $9 Price Target
MiNK Therapeutics Analyst Ratings
MiNK Therapeutics' Promising Clinical Trials and Strategic Expansion Set to Enhance Stock Value
MiNK Therapeutics 2Q Loss/Shr 7c >INKT
Express News | Mink Therapeutics Inc - Qtrly Shr Loss $0.07
Express News | MiNK Therapeutics Q2 2024 GAAP EPS $(0.07) Beats $(0.10) Estimate
Express News | Mink Reports Second Quarter 2024 Results and Business Update
MiNK Reports Second Quarter 2024 Results and Business Update
Express News | Mink Therapeutics to Provide Corporate Update and Second Quarter 2024 Financial Report
Analysis
Price Target
No Data
No Data